97 related articles for article (PubMed ID: 8612292)
21. Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.
Vlahakis SR; Bren GD; Algeciras-Schimnich A; Trushin SA; Schnepple DJ; Badley AD
Clin Pharmacol Ther; 2007 Sep; 82(3):294-9. PubMed ID: 17361127
[TBL] [Abstract][Full Text] [Related]
22. HIV-Tat promotes cellular proliferation and inhibits NGF-induced differentiation through mechanisms involving Id1 regulation.
Bergonzini V; Delbue S; Wang JY; Reiss K; Prisco M; Amini S; Khalili K; Peruzzi F
Oncogene; 2004 Oct; 23(46):7701-11. PubMed ID: 15361847
[TBL] [Abstract][Full Text] [Related]
23. RCAS1 induced by HIV-Tat is involved in the apoptosis of HIV-1 infected and uninfected CD4+ T cells.
Minami R; Yamamoto M; Takahama S; Miyamura T; Watanabe H; Suematsu E
Cell Immunol; 2006 Sep; 243(1):41-7. PubMed ID: 17250817
[TBL] [Abstract][Full Text] [Related]
24. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma.
Demirhan I; Chandra A; Mueller F; Mueller H; Biberfeld P; Hasselmayer O; Chandra P
J Hum Virol; 2000; 3(3):137-43. PubMed ID: 10881993
[TBL] [Abstract][Full Text] [Related]
25. IL-7 and the HIV Tat protein act synergistically to down-regulate CD127 expression on CD8 T cells.
Faller E; Kakal J; Kumar R; Macpherson P
Int Immunol; 2009 Mar; 21(3):203-16. PubMed ID: 19147839
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.
Mukhtar M; Duan L; Bagasra O; Pomerantz RJ
Gene Ther; 1996 Aug; 3(8):725-30. PubMed ID: 8854098
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 Tat modulates T-bet expression and induces Th1 type of immune response.
Kulkarni A; Ravi DS; Singh K; Rampalli S; Parekh V; Mitra D; Chattopadhyay S
Biochem Biophys Res Commun; 2005 Apr; 329(2):706-12. PubMed ID: 15737643
[TBL] [Abstract][Full Text] [Related]
28. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein.
Li CJ; Friedman DJ; Wang C; Metelev V; Pardee AB
Science; 1995 Apr; 268(5209):429-31. PubMed ID: 7716549
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro.
Hsu MC; Dhingra U; Earley JV; Holly M; Keith D; Nalin CM; Richou AR; Schutt AD; Tam SY; Potash MJ
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6395-9. PubMed ID: 8341644
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of HIV-1 tat-induced transactivation and apoptosis by the divalent metal chelators, fusaric acid and picolinic acid-implications for HIV-1 dementia.
Ramautar A; Mabandla M; Blackburn J; Daniels WM
Neurosci Res; 2012 Sep; 74(1):59-63. PubMed ID: 22698778
[TBL] [Abstract][Full Text] [Related]
31. Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis.
Ehret A; Westendorp MO; Herr I; Debatin KM; Heeney JL; Frank R; Krammer PH
J Virol; 1996 Sep; 70(9):6502-7. PubMed ID: 8709290
[TBL] [Abstract][Full Text] [Related]
32. [Therapeutic potential of Ro 5-3335. New active benzodiazepine in vitro against HIV-1 viruses resistant or non-resistant to AZT].
Camsonne R; Bigot MC; Fusibet H; Moulin MA
Therapie; 1993; 48(2):105-7. PubMed ID: 8351676
[TBL] [Abstract][Full Text] [Related]
33. HIV type 1 Tat protein inhibits interleukin 12 production by human peripheral blood mononuclear cells.
Ito M; Ishida T; He L; Tanabe F; Rongge Y; Miyakawa Y; Terunuma H
AIDS Res Hum Retroviruses; 1998 Jul; 14(10):845-9. PubMed ID: 9671213
[TBL] [Abstract][Full Text] [Related]
34. Turnabout on AIDS drug.
Science; 1992 Jan; 255(5041):154. PubMed ID: 1553539
[No Abstract] [Full Text] [Related]
35. HIV replication in chronically infected macrophages is not inhibited by the Tat inhibitors Ro-5-3335 and Ro-24-7429.
Dunne AL; Siregar H; Mills J; Crowe SM
J Leukoc Biol; 1994 Sep; 56(3):369-73. PubMed ID: 8083610
[TBL] [Abstract][Full Text] [Related]
36. HIV type 1 Tat protein enhances activation-but not Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals.
Katsikis PD; García-Ojeda ME; Torres-Roca JF; Greenwald DR; Herzenberg LA; Herzenberg LA
Int Immunol; 1997 Jun; 9(6):835-41. PubMed ID: 9199966
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic effect on lymphocytes of Tat from human immunodeficiency virus (HIV-1).
Benjouad A; Mabrouk K; Moulard M; Gluckman JC; Rochat H; Van Rietschoten J; Sabatier JM
FEBS Lett; 1993 Mar; 319(1-2):119-24. PubMed ID: 8095908
[TBL] [Abstract][Full Text] [Related]
38. New AIDS drug poised to move into development.
Science; 1991 Dec; 254(5039):1715. PubMed ID: 1763318
[No Abstract] [Full Text] [Related]
39. HIV-1 Tat protein enhances microtubule polymerization.
de Mareuil J; Carre M; Barbier P; Campbell GR; Lancelot S; Opi S; Esquieu D; Watkins JD; Prevot C; Braguer D; Peyrot V; Loret EP
Retrovirology; 2005 Feb; 2():5. PubMed ID: 15691386
[TBL] [Abstract][Full Text] [Related]
40. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Connell EV; Hsu MC; Richman DD
Antimicrob Agents Chemother; 1994 Feb; 38(2):348-52. PubMed ID: 7514858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
